Thera-SAbDab

GLEMBATUMUMAB

> Structural Summary

Therapeutic	Glembatumumab
Target	GPNMB
Heavy Chain	QVQLQESGPGLVKPSQTLSLTCTVSGGSISSFNYYWSWIRHHPGKGLEWIGYIYYSGSTYSNPSLKSRVTISVDTSKNQFSLTLSSVTAADTAVYYCARGYNWNYFDYWGQGTLVTVSS
Light Chain	EIVMTQSPATLSVSPGERATLSCRASQSVDNNLVWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPWTFGQGTKVEIK
100% seqID Fv Structure	None
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

There are currently no PDB structures close in sequence to this therapeutic Fv. Click here to build a model with ABodyBuilder.

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb ADC
Isotype	G2
Highest Clinical Trial (June '19)	Phase-III
Estimated Status (June '19)	Discontinued
Recorded Developmental Technology	na
INN Year Proposed	2015
INN Year Recommended	2016
Companies Involved	CuraGen Corporation, Celldex Therapeutics Inc, National Cancer Institute (USA)
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Brain cancer, Breast cancer, Malignant melanoma, Osteosarcoma, Squamous cell cancer, Uveal melanoma
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]